

# Iain M. Cockburn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8154928/publications.pdf>

Version: 2024-02-01

41  
papers

8,458  
citations

186265

28  
h-index

330143

37  
g-index

60  
all docs

60  
docs citations

60  
times ranked

4647  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patents and the Global Diffusion of New Drugs. <i>American Economic Review</i> , 2016, 106, 136-164.	8.5	102
2	Deals not done: Sources of failure in the market for ideas. <i>Strategic Management Journal</i> , 2015, 36, 976-986.	7.3	33
3	Why are some regions more innovative than others? The role of small firms in the presence of large labs. <i>Journal of Urban Economics</i> , 2014, 81, 149-165.	4.4	113
4	The Hidden Cost Of Low Prices: Limited Access To New Drugs In India. <i>Health Affairs</i> , 2014, 33, 1567-1575.	5.2	31
5	Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms. <i>Research Policy</i> , 2013, 42, 529-541.	6.4	14
6	Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity. <i>Information Systems Research</i> , 2012, 23, 42-59.	3.7	301
7	Entry and Patenting in the Software Industry. <i>Management Science</i> , 2011, 57, 915-933.	4.1	118
8	Diffusion of New Drugs in the Post-TRIPS Era. <i>International Journal of the Economics of Business</i> , 2011, 18, 203-224.	1.7	8
9	Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases. <i>Clinical Trials</i> , 2010, 7, 719-734.	1.6	28
10	Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy. <i>Capitalism and Society</i> , 2010, 5, .	0.3	19
11	Not Invented Here? Innovation in company towns. <i>Journal of Urban Economics</i> , 2010, 67, 78-89.	4.4	90
12	Patents and the survival of Internet-related IPOs. <i>Research Policy</i> , 2010, 39, 214-228.	6.4	113
13	Patent thickets, licensing and innovative performance. <i>Industrial and Corporate Change</i> , 2010, 19, 899-925.	2.8	67
14	<scp>Patents, Thickets and the Financing of Earlyâ€­Stage Firms: Evidence from the Software Industry</scp>. <i>Journal of Economics and Management Strategy</i> , 2009, 18, 729-773.	0.8	121
15	Faster, smaller, cheaper: an hedonic price analysis of PDAs. <i>Applied Economics</i> , 2008, 40, 2839-2856.	2.2	32
16	The Impact of Incremental Innovation in Biopharmaceuticals. <i>Pharmacoeconomics</i> , 2006, 24, 69-86.	3.3	42
17	Gone but not forgotten: knowledge flows, labor mobility, and enduring social relationships. <i>Journal of Economic Geography</i> , 2006, 6, 571-591.	3.0	500
18	The Market For Follow-On Biologics: How Will It Evolve?. <i>Health Affairs</i> , 2006, 25, 1291-1301.	5.2	69

#	ARTICLE	IF	CITATIONS
19	The Changing Structure Of The Pharmaceutical Industry. Health Affairs, 2004, 23, 10-22.	5.2	195
20	Impact of Clinical Trial Results on National Trends in $\beta$ -Blocker Prescribing, 1996-2002. JAMA - Journal of the American Medical Association, 2004, 291, 54.	7.4	84
21	A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clinical Therapeutics, 2003, 25, 1503-1517.	2.5	61
22	The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems. International Journal of Industrial Organization, 2003, 21, 1227-1253.	1.2	304
23	National trends in asthma visits and asthma pharmacotherapy, 1978-2002. Journal of Allergy and Clinical Immunology, 2003, 111, 729-735.	2.9	70
24	O Brave New Industry, That Has Such Patents in It! Reflections on the Economic Consequences of Patenting DNA. Advances in Genetics, 2003, 50, 385-398.	1.8	4
25	Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Journal of Health Economics, 2001, 20, 1033-1057.	2.7	172
26	New Pills for Poor People? Empirical Evidence after GATT. World Development, 2001, 29, 265-289.	4.9	100
27	Untangling the origins of competitive advantage. Strategic Management Journal, 2000, 21, 1123-1145.	7.3	376
28	Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clinical Therapeutics, 1999, 21, 917-924.	2.5	4
29	Loss of Work Productivity due to Illness and Medical Treatment. Journal of Occupational and Environmental Medicine, 1999, 41, 948-953.	1.7	117
30	Analysis of Patent Data: A Mixed-Poisson-Regression-Model Approach. Journal of Business and Economic Statistics, 1998, 16, 27.	2.9	33
31	Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery. Journal of Industrial Economics, 1998, 46, 157-182.	1.3	797
32	Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. RAND Journal of Economics, 1997, 28, 426.	2.3	167
33	Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery. RAND Journal of Economics, 1996, 27, 32.	2.3	898
34	Mixed Poisson Regression Models with Covariate Dependent Rates. Biometrics, 1996, 52, 381.	1.4	151
35	Public-private interaction in pharmaceutical research. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12725-12730.	7.1	105
36	Opportunity costs and entrepreneurial activity. Journal of Business Venturing, 1995, 10, 95-106.	6.3	256

#	ARTICLE	IF	CITATIONS
37	Measuring Competence? Exploring Firm Effects in Pharmaceutical Research. Strategic Management Journal, 1994, 15, 63-84.	7.3	2,049
38	DO FIRMS CHANGE CAPABILITIES BY HIRING NEW PEOPLE? A STUDY OF THE ADOPTION OF SCIENCE-BASED DRUG DISCOVERY. Advances in Strategic Management, 0, , 133-159.	0.1	81
39	Patent Thickets, Licensing and Innovative Performance. SSRN Electronic Journal, 0, , .	0.4	10
40	Hedonic Analysis of Arthritis Drugs. , 0, , 439-458.		15
41	National Bureau of Economic Research Patent Database: Audio of Presentation. SSRN Electronic Journal, 0, , .	0.4	0